Effects of Introducing Xpert MTB/RIF on Diagnosis and Treatment of Drug-Resistant Tuberculosis Patients in Indonesia: A Pre-Post Intervention Study

Sanne C van Kampen, Nugroho H Susanto, Sumanto Simon, Shinta D Astiti, Roni Chandra, Erlina Burhan, Muhammad N Farid, Kendra Chittenden, Dyah E Mustikawati, Bachti Alisjahbana, Sanne C van Kampen, Nugroho H Susanto, Sumanto Simon, Shinta D Astiti, Roni Chandra, Erlina Burhan, Muhammad N Farid, Kendra Chittenden, Dyah E Mustikawati, Bachti Alisjahbana

Abstract

Background: In March 2012, the Xpert MTB/RIF assay (Xpert) was introduced in three provincial public hospitals in Indonesia as a novel diagnostic to detect tuberculosis and rifampicin resistance among high risk individuals.

Objective: This study assessed the effects of using Xpert in place of conventional solid and liquid culture and drug-susceptibility testing on case detection rates, treatment initiation rates, and health system delays among drug-resistant tuberculosis (TB) patients.

Methods: Cohort data on registration, test results and treatment initiation were collected from routine presumptive patient registers one year before and one year after Xpert was introduced. Proportions of case detection and treatment initiation were compared using the Pearson Chi square test and median time delays using the Mood's Median test.

Results: A total of 975 individuals at risk of drug-resistant TB were registered in the pre-intervention year and 1,442 in the post-intervention year. After Xpert introduction, TB positivity rate increased by 15%, while rifampicin resistance rate reduced by 23% among TB positive cases and by 9% among all tested. Second-line TB treatment initiation rate among rifampicin resistant patients increased by 19%. Time from client registration to diagnosis was reduced by 74 days to a median of a single day (IQR 0-4) and time from diagnosis to treatment start was reduced by 27 days to a median of 15 days (IQR 7-51). All findings were significant with p<0.001.

Conclusion: Compared to solid and liquid culture and drug-susceptibility testing, Xpert detected more TB and less rifampicin resistance, increased second-line treatment initiation rates and shortened time to diagnosis and treatment. This test holds promise to improve rapid case finding and management of drug-resistant TB patients in Indonesia.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Diagnosis and treatment of individuals…
Fig 1. Diagnosis and treatment of individuals at risk of multidrug-resistant pulmonary TB at three provincial hospitals in Java, Indonesia.
The flowchart shows the number of tested, detected and treated individuals in two cohort years. From March 2011 to Feb 2012 (Year 1), individuals were tested with conventional culture and drug-susceptibility testing. From March 2012 to February 2013 (Year 2), individuals were tested with culture and drug-susceptibility testing or Xpert MTB/RIF. Abbreviations: TB, tuberculosis; DST, drug-susceptibility testing; RIF, rifampicin; MDR-TB, multidrug-resistant TB; N, number.
Fig 2. Time to diagnosis and treatment…
Fig 2. Time to diagnosis and treatment of rifampicin-resistant TB patients in three provincial hospitals in Java, Indonesia.
These figures show Kaplan Meier time-to-event graphs of health system delays (a), diagnostic delays (b) and treatment delays (c) for rifampicin resistance TB patients detected with culture drug-susceptibility testing from March 2011 to February 2012 and Xpert MTB/RIF from March 2012 to February 2013. Abbreviations: TB, tuberculosis; DST, drug-susceptibility testing; RIF, rifampicin.

References

    1. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system Geneva: WHO; 2011.
    1. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children Policy update. Geneva: WHO; 2013.
    1. World Health Organization; Xpert MTB/RIF implementation manual: technical and operational ‘how-to’; practical considerations Geneva: WHO; 2014.
    1. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults (Review). Cochrane Database Syst Rev. 2014; 10.1002/14651858.CD009593.pub3
    1. Chang K, Lu W, Wang L, Zhang K, Jia S, Li F, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect. 2012;64:580–8. 10.1016/j.jinf.2012.02.012
    1. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and eff ectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011; 10.1016/S0140-6736(11)60438-8
    1. Creswell J, Codlin AJ, Andre E, Micek MA, Bedru A, Carter EJ, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Inf Dis. 2014;14(2):12.
    1. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical eff ect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383:12 10.1016/S0140-6736(13)62345-4
    1. Hanrahan CF, Selibas K, Deery CB, Dansey H, Clouse K, Bassett J, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS ONE. 2013;8(6):e65421 10.1371/journal.pone.0065421
    1. Yoon C, Cattamanchi A, Davis LC, Worodria W, Den Boon S, Kalema N, et al. Impact of Xpert MTB/RIF testing on tuberculosis management and outcomes in hospitalized patients in Uganda. PLoS ONE. 2012;7(11):e48599 10.1371/journal.pone.0048599
    1. Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett J, et al. Point-of-care Xpert MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013;17(3):368–72. 10.5588/ijtld.12.0392
    1. Clouse K, Page-Shipp L, Dansey H, Moatlhodi B, Scott L, Bassett J, et al. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012;102(805–807). 10.7196/samj.5851
    1. National Tuberculosis Control Program. National action plan: Programmatic management of drug resistance tuberculosis, Indonesia 2011–2014 Jakarta: Ministry of Health of the Republic of Indonesia; 2011.
    1. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M, et al. False-positive Xpert MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis. 2014;18(7):876–8. 10.5588/ijtld.13.0853
    1. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 2012;74:207–9. 10.1016/j.diagmicrobio.2012.06.013
    1. Van Rie A, Mellet K, John MA, Scott L, Page-Shipp L, Dansey H, et al. False-positive rifampicin resistance on Xpert MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012;16(2):206–8. 10.5588/ijtld.11.0395
    1. Van Deun A, Aung KJM, Bola V, Lebeke R, Hossain MA, De Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013;51(8):2633–40. 10.1128/JCM.00553-13
    1. Rigouts L, Gumusboga M, De Rijk WB, Nduwamahoro E, Uwizeye C, De Jong B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol. 2013;51(8):2641–5. 10.1128/JCM.02741-12

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi